Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...
The last time I wrote about Annexon (ANNX) it was with respect to a Seeking Alpha article entitled "Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place". In this article ...
ATLANTA — The Food and Drug Administration announced a new warning about a possible link from Johnson & Johnson’s COVID-19 vaccine and a rare neurological reaction. The new warning flagged ...
A Guillain-Barre Syndrome (GBS) outbreak has been reported in Madhya Pradesh's Neemuch district. According to the health officials, two children have died, and 18 cases (9 confirmed and 9 suspected) ...
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late--stage development, global regulatory and operational expertise as MinervaX enters its next phase of ...
Researchers in Norway studied rates of fatalities and long-term neurodevelopmental disorders among 866 infants diagnosed with GBS infection. Children with GBS meningitis died at higher rates than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results